MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1089/bsp.2009.0032

Медицинская библиотека · Biosecurity and bioterrorism : biodefense strategy, practice, and science · 2009

Alphavirus antiviral drug development: scientific gap analysis and prospective research areas.

Reichert Erin, Clase Amanda, Bacetty Ada, Larsen Joseph

СтатьяОбзорПеревод в очереди

Аннотация

The New World alphaviruses Venezuelan equine encephalitis virus (VEEV), eastern equine encephalitis virus (EEEV), and western equine encephalitis virus (WEEV) pose a significant threat to human health as the etiological agents of serious viral encephalitis through natural infection as well as through their potential use as a biological weapon. At present, there is no FDA-approved medical treatment for infection with these viruses. The Defense Threat Reduction Agency, Joint Science and Technology Office for Chemical and Biological Defense (DTRA/JSTO), is currently funding research aimed at developing antiviral drugs and vaccines against VEEV, EEEV, and WEEV. A review of antiviral drug discovery efforts for these viruses revealed significant gaps in the data, assays, and models required for successful drug development. This review provides a description of these gaps and highlights specific critical research areas for the development of a target-based drug discovery program for the VEEV, EEEV, and WEEV nonstructural proteins. These efforts will increase the probability of the successful development of a pharmaceutical intervention against these viral threat agents.

Для цитирования: Reichert Erin, Clase Amanda, Bacetty Ada, Larsen Joseph. Alphavirus antiviral drug development: scientific gap analysis and prospective research areas.. Biosecurity and bioterrorism : biodefense strategy, practice, and science. 2009. DOI: 10.1089/bsp.2009.0032.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.